Innoviva (INVA) Current Deferred Revenue (2010 - 2026)
Innoviva's Current Deferred Revenue came in at $6.02 million for Q2 2026, up 92.5% from $3.13 million a year earlier and up 63.6% from the prior quarter.
Powered by 
Analysis
Innoviva (INVA) Current Deferred Revenue (2010 - 2026) Analysis & Trends
At the end of FY2025, Innoviva's Current Deferred Revenue was $4.27 million, up 279.2% from FY2024.
- Current Deferred Revenue carries a three-year compound annual growth rate of 26.8% (FY2022 to FY2025).
- Going back by year, Current Deferred Revenue was $1.13 million in FY2024 (-11.8%), $1.28 million in FY2023 (-39.0%) and $2.09 million in FY2022.
- The five-year range for quarterly Current Deferred Revenue is $717,000 (Q3 2024) to $13.57 million (Q3 2025).
- Year-over-year, Current Deferred Revenue has increased for three consecutive quarters, with growth averaging 149.0% over the last six quarters.
- The fastest year-over-year change in Current Deferred Revenue over five years came in Q4 2025 (growth of 279.2%), and the weakest in Q2 2024 (a decline of 73.7%).
- Business Quant data shows INVA's Current Deferred Revenue at $3.68 million (Q1 2026), $4.27 million (Q4 2025) and $13.57 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Innoviva | 1.54 Bn | -750.13 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.02 Mn |
| Mar 31, 2026 | 3.68 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 13.57 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 717,000.00 |
| Jun 30, 2024 | 855,000.00 |
| Mar 31, 2024 | 987,000.00 |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.85 Mn |
| Sep 30, 2017 | 885,000.00 |
| Jun 30, 2017 | 885,000.00 |
| Mar 31, 2017 | 885,000.00 |
| Dec 31, 2016 | 885,000.00 |
API Access
Innoviva Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=INVA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "INVA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=INVA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();